LEXX (Lexaria Bioscience) Short Interest


LEXX Lexaria Bioscience Corp LEXX
28 GF Score
Price $0.54
GF Value $0.75
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lexaria Bioscience Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LEXX vs MBRX, ICU, INTI: Short Interest Comparison

For the Biotechnology subindustry, Lexaria Bioscience's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexaria Bioscience Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Short Interest distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Short Interest falls into.


LEXX
28GF Score
Lexaria Bioscience Corp LEXX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be undervalued. The current stock price of $0.54 is trading 27.7% below its estimated GF Value™ of $0.75. GuruFocus considers Lexaria Bioscience to be Modestly Undervalued.

Key valuation signals for LEXX:

  • Short Interest:
  • GF Value™: $0.75 vs. price of $0.54 (27.7% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
28GF Score

Get the complete analysis for LEXX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$0.75
GF Value